['lung cancer']
['azd9291 dosing']

        Inclusion Criteria:

          1. Provision of informed consent prior to any study specific procedures.

          2. Adults (according to China regulations for age of majority)

          3. Histological or cytological confirmed locally advanced NSCLC (stage IIIB) or
             metastatic (stage IV) NSCLC, not amenable to curative surgery or radiotherapy.

          4. Patients who have progressed following prior therapy with an EGFR-TKI agent.

        Exclusion Criteria:

          1. Patients who disagree to participate this study.

          2. Patients whose medical objection was recorded to use the existing data from medical
             practice for scientific research.
      